Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Shares of Synergy Pharmaceuticals (SGYP) rose 10% to $4.00 in Friday trading. On Thursday, Cantor Fitzgerald started coverage of the New York firm's shares with an overweight rating and an $11 price target.

Shares of Bluebird Bio (BLUE) gained 6.3% to $84.15 on the heels of an upgrade to buy from hold by analysts at Maxim Group. In a note on Friday, the analysts said they believe that the event that could "break BLUE shares out of the current valuation range is bb2121 CAR-T data in multiple myeloma" that will be presented at the American Society of Clinical Oncology's annual meeting. The conference takes place June 2 - 6 in Chicago.

Among the other biotech movers was DBV Technologies (DBVT) . The Bagneux, France-based firm's American depository shares were up 2.2% to $34.90.

More from Health

Whether you're retiring in 2019 or you have another decade to go, when the time arrives, you want to be ready. Just in time for the holidays, TheStreet delivers you the ultimate guide to retiring rich.